Methamphetamine
Active ingredient: Methamphetamine Hydrochloride
In short: Methamphetamine hydrochloride tablets, USP is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older.
What is Methamphetamine used for?
Methamphetamine hydrochloride tablets, USP is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older.
âš Boxed warning (FDA's strongest warning)
METHAMPHETAMINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including METHAMPHETAMINE, can result in overdose and death
,
and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing METHAMPHETAMINE, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout METHAMPHETAMINE treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction
.
Methamphetamine dosage
Prior to treating patients with methamphetamine hydrochloride tablets, USP, assess:
for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical examination) .
the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating methamphetamine hydrochloride tablets, USP .
Administer methamphetamine hydrochloride tablets, USP orally once daily or in two divided doses daily. Avoid taking methamphetamine hydrochloride tablets, USP late in the evening due to the risk of insomnia.
For pediatric patients 6 years of age and older, the recommended starting dosage is 5 mg methamphetamine hydrochloride tablets, USP once or twice daily. The daily dosage may be increased in increments of 5 mg at weekly intervals based on clinical response of the patient. The recommended dosage range is 20 mg to 25 mg daily.
Agents that alter urinary pH can impact excretion and alter blood levels of amphetamine. Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g., sodium bicarbonate) increase blood levels. Adjust methamphetamine dosage based on clinical response .
How to take Methamphetamine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Abuse, Misuse, and Addiction
Educate patients and their families about the risks of abuse, misuse, and addiction of methamphetamine hydrochloride tablets, USP , which can lead to overdose and death, and proper disposal of any unused drug . Advise patients to store methamphetamine hydrochloride tablets, USP in a safe place, preferably locked, and instruct patients to not give methamphetamine hydrochloride tablets, USP to anyone else.
Risks to Patients with Serious Cardiac Disease
Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death with methamphetamine hydrochloride tablets, USP use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease .
Increased Blood Pressure and Heart Rate
Instruct patients that methamphetamine hydrochloride tablets, USP can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects . …
Warnings & precautions
Do not take this medicine if: Methamphetamine hydrochloride tablets, USP is contraindicated in patients with:
known hypersensitivity to amphetamine, or other components of methamphetamine. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products .
taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of the risk of hypertensive crisis .
Methamphetamine has a high potential for abuse and misuse. The use of methamphetamine exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Methamphetamine can be diverted for non-medical use into illicit channels or distribution . Misuse and abuse of CNS stimulants, including methamphetamine, can result in overdose and death , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing methamphetamine, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store methamphetamine in a safe place, preferably locked, and instruct patients to not give methamphetamine to anyone else. Throughout methamphetamine treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
Sudden death has been reported in patients with structural cardiac abnormalities and other serious cardiac disease who were treated with CNS stimulants at recommended ADHD dosage. …
Methamphetamine side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Abuse, Misuse, and Addiction
Hypersensitivity to amphetamine products or other ingredients of methamphetamine
Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors
Risks to Patient with Serious Cardiac Disease
Increased Blood Pressure and Heart Rate
Psychiatric Adverse Reactions
Long-Term Suppression of Growth in Pediatric Patients
Peripheral Vasculopathy, including Raynaud’s Phenomenon
Seizures
Serotonin Syndrome
Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
The following adverse reactions associated with the use of methamphetamine were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular: Elevation of blood pressure, tachycardia and palpitation. Fatal cardiorespiratory arrest has been reported, mostly in the context of abuse/misuse
Central Nervous System: Psychotic episodes reported at recommended doses. Dizziness, dysphoria, overstimulation, euphoria, insomnia, tremor, restlessness and headache. …
Drug interactions
Table 1 presents clinically important drug interactions with methamphetamine hydrochloride tablets, USP .
Table 1: Clinically Important Drug Interactions with methamphetamine hydrochloride tablets, USP
Monoamine Oxidase Inhibitors (MAOI)
Clinical Impact: | MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.
Intervention: | Concomitant use of methamphetamine hydrochloride tablets, USP with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOI treatment is contraindicated .
Serotonergic Drugs
Clinical Impact: | The concomitant use of amphetamines, including methamphetamine hydrochloride tablets, USP , and serotonergic drugs increases the risk of serotonin syndrome.
Intervention: | Initiate methamphetamine hydrochloride tablets, USP with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during methamphetamine hydrochloride tablets, USP initiation or dosage increase. …
About this medicine
Methamphetamine hydrochloride tablets, USP contain methamphetamine, a central nervous system stimulant, in the form of hydrochloride salt. Methamphetamine hydrochloride is chemically known as (S) N,α dimethylbenzeneethanamine hydrochloride with molecular formula of C10H15N.HCl and molecular weight of 185.73 g/mol It has the following structural formula:
Methamphetamine hydrochloride tablets, USP contain 5 mg of methamphetamine hydrochloride, USP for oral administration.
Inactive Ingredients:
Corn starch, lactose monohydrate, stearic acid and talc.
How it works: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in the treatment of ADHD is not known. Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d0905e2c-a02f-ec4f-59a3-6f7ad0acbbf6. Read the full official label on DailyMed.